Turner A G, Durrant K R, Malpas J S
Br J Urol. 1979 Apr;51(2):121-4. doi: 10.1111/j.1464-410x.1979.tb02844.x.
Thirty-seven patients were studied in a controlled clinical trial to assess the value of Adriamycin and Bleomycin in the treatment of advanced carcinoma of the bladder. The previously reported high response rates for both drugs were not observed in this trial. Administration of Bleomycin was accompanied by a toxicity rate so high that treatment had to be abandoned. Neither Adriamycin nor Bleomycin, therefore, used as single agents, have a role in the chemotherapy of advanced bladder cancer. Other agents should be investigated and assessed by controlled clinical trials that are disease-orientated rather than drug-orientated.
在一项对照临床试验中，对37名患者进行了研究，以评估阿霉素和博来霉素在治疗晚期膀胱癌中的价值。在该试验中未观察到之前报道的这两种药物的高缓解率。博来霉素的给药伴随着如此高的毒性率，以至于不得不放弃治疗。因此，单独使用阿霉素或博来霉素在晚期膀胱癌的化疗中均无作用。其他药物应以疾病为导向而非以药物为导向的对照临床试验进行研究和评估。
